December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Natera, Inc. - Common Stock (NQ:NTRA)

198.37 +11.53 (+6.17%)
Streaming Delayed Price Updated: 3:04 PM EDT, Mar 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Natera, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
News headline image
Employees Volunteer Over 1,500 Hours During Natera’s Annual Volunteer Month
From Natera, Inc.
Via Business Wire
News headline image
Druckenmiller Opens Position In Amazon, Closes Microsoft — Here's More Of Duquesne's Biggest Q3 Moves ↗
Stanley Druckenmiller's Duquesne Family Office Q3 13F reinforces the firm's reputation for agile and opportunity-driven asset allocation. 
Via Benzinga
News headline image
Natera Integrates with Flatiron Health’s OncoEMR® Platform
From Natera, Inc.
Via Business Wire
News headline image
Earnings Scheduled For November 6, 2025 ↗
 
Via Benzinga
News headline image
1 Healthcare Stock with Impressive Fundamentals and 2 Facing Headwinds
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have caused the... 
Via StockStory
Topics Stocks
News headline image
2 Surging Stocks with Impressive Fundamentals and 1 We Question
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro... 
Via StockStory
News headline image
Natera (NTRA) Q3 2025 Earnings Call Transcript ↗
Natera (NTRA) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
NTRA Q3 Deep Dive: Oncology Momentum and New Product Expansion Drive Guidance Increase
Genetic testing company Natera (NASDAQ:NTRA). beat Wall Street’s revenue expectations in Q3 CY2025, with sales up 34.7% year on year to $592.2 million. The company’s full-year revenue guidance of $2.22... 
Via StockStory
News headline image
Natera Inc (NASDAQ:NTRA) Q3 2025 Earnings: Revenue Soars Past Estimates, Shares Climb on Raised Guidance ↗
Natera (NTRA) Q3 2025 results beat revenue forecasts with $592.2M, driven by strong oncology test growth. The company raised its full-year 2025 guidance. 
Via Chartmill
News headline image
Natera (NASDAQ:NTRA) Delivers Impressive Q3
Genetic testing company Natera (NASDAQ:NTRA). reported Q3 CY2025 results beating Wall Street’s revenue expectations, with sales up 34.7% year on year to $592.2 million. The company’s full-year revenue... 
Via StockStory
News headline image
Natera Reports Third Quarter 2025 Financial Results
From Natera, Inc.
Via Business Wire
News headline image
Natera (NTRA) Reports Earnings Tomorrow: What To Expect
Genetic testing company Natera (NASDAQ:NTRA). will be reporting earnings this Thursday after the bell. Here’s what to expect. 
Via StockStory
Topics Artificial Intelligence
News headline image
2 Unpopular Stocks That Should Get More Attention and 1 We Ignore
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps... 
Via StockStory
News headline image
Natera Announces Expansion to 20 Genes for its Fetal Focus™ Single-Gene NIPT
From Natera, Inc.
Via Business Wire
News headline image
Natera to Report its Third Quarter Results on November 6, 2025
From Natera, Inc.
Via Business Wire
News headline image
Natera Reports Strong Advanced Adenoma Data from Prospective PROCEED-CRC Trial, Demonstrating 22.5% Sensitivity and 91.5% Specificity
From Natera, Inc.
Via Business Wire
News headline image
Halper Sadeh LLC Encourages Natera Inc. Shareholders to Contact the Firm to Discuss Their Rights
From Halper Sadeh LLC
Via Business Wire
News headline image
A Glimpse Into The Expert Outlook On Natera Through 8 Analysts ↗
 
Via Benzinga
News headline image
Reflecting On Immuno-Oncology Stocks’ Q2 Earnings: Natera (NASDAQ:NTRA)
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the immuno-oncology industry, including Natera (NASDAQ:NTRA) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
Why Are Natera (NTRA) Shares Soaring Today
Shares of genetic testing company Natera (NASDAQ:NTRA). jumped 7.2% in the afternoon session after the company announced promising results from its phase 3 IMvigor011 clinical trial for its Signatera... 
Via StockStory
Topics Intellectual Property
News headline image
Successful IMvigor011 Trial Achieves 41% Improvement in Overall Survival for Bladder Cancer Patients
From Natera, Inc.
Via Business Wire
News headline image
Natera Named to Fast Company’s Next Big Things in Tech List
From Natera, Inc.
Via Business Wire
News headline image
Here's How Much $1000 Invested In Natera 5 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
Natera to Host Investor Call on October 23, 2025 to Discuss ESMO Findings
From Natera, Inc.
Via Business Wire
News headline image
Natera to Present 14 Studies at ESMO, Including IMvigor011 Oral Presentation in Presidential Symposium
From Natera, Inc.
Via Business Wire
News headline image
2 of Wall Street’s Favorite Stocks on Our Watchlist and 1 That Underwhelm
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because... 
Via StockStory
Topics Retirement
News headline image
Enrollment Tops 1,600 in Natera’s EXPAND Trial of Single Gene NIPT
From Natera, Inc.
Via Business Wire
News headline image
Natera Announces Publication of Signatera™ Validation Study in Testicular Cancer
From Natera, Inc.
Via Business Wire
News headline image
Signatera™ Surveillance Testing Identified 100% of Uterine Cancer Recurrences in Advance of Imaging, New Study Shows
From Natera, Inc.
Via Business Wire
News headline image
2 Safe-and-Steady Stocks to Target This Week and 1 Facing Headwinds
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere. 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.